Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown origin. Despite the fact that the guidelines on the diagnosis and management of the disease were updated in 2015, incorporating novel agents recently introduced in the therapeutic approach of IPF, there is a lack of data on the epidemiology, disease status, and treatment in clinical practice. Contemporary data provided by national registries in IPF provide valuable information to guide clinical management of the disease in the real-world setting, adjusted to the local needs. Objective: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF) is a Greek observational registry aiming at gaining further knowledge on the characteristics, management, progression, and outcomes of patients with IPF treated under real-world, clinical practice conditions in Greece. Methods: Approximately 300 patients will be enrolled consecutively in seven reference centers, constituting the largest IPF registry ever established in Greece. Conclusion: This registry is expected to provide data on the characteristics of IPF patients in Greece and the entire clinical management during the course of the disease.

Keywords:
Greece, Idiopathic pulmonary fibrosis registry, INDULGE IPF, IPF
1.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2.
Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
3.
Anto JM, Cullinan P: Clusters, classification and epidemiology of interstitial lung diseases: concepts, methods and critical reflections. Eur Respir J Suppl 2001; 32: 101s–106s.
4.
Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, et al: Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J 2017; 49: 1601592.
5.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
6.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
7.
Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.
8.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
9.
Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C: Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 2014; 58: 13–19.
10.
Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061–1069.
11.
Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, et al: Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis. Chest 2015; 148: 196–201.
12.
Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, et al: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976–985.
13.
Coward WR, Saini G, Jenkins G: The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010; 4: 367–388.
14.
Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK: Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med 2016; 113: 74–79.
15.
Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al: An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192:e3–e19.
16.
Wilson JW, du Bois RM, King TE Jr: Challenges in pulmonary fibrosis: 8 – The need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008; 63: 285–287.
17.
Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, et al: The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 2014; 15: 63.
18.
Musellim B, Okumus G, Uzaslan E, Akgun M, Cetinkaya E, Turan O, et al: Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J 2014; 8: 55–62.
19.
Karakatsani A, Papakosta D, Rapti A, Anto-niou KM, Dimadi M, Markopoulou A, et al: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122–1129.
20.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967–972.
21.
Hutchinson J, Fogarty A, Hubbard R, McKee-ver T: Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795–806.
22.
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ: Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
23.
Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al: Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129–137.
24.
Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, et al: The incidence of interstitial lung disease 1995–2005: a Danish nationwide population-based study. BMC Pulm Med 2008; 8: 24.
25.
Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al: Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186–196.
26.
O’Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, et al: Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res 2016; 3:e000108.
27.
Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D: Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res 2014; 1:e000010.
28.
Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al: EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J 2017, Epub ahead of print.
29.
Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, et al: Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017; 195: 78–85.
30.
Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, et al: Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72: 340–346.
31.
Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al: Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71: 429–435.
32.
Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, et al: Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study. Pulm Pharmacol Ther 2017; 46: 48–53.
33.
Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N: Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016; 5:E78.
34.
Cottin V, Maher T: Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 58–64.
35.
Borie R, Justet A, Beltramo G, Manali ED, Pradère P, Spagnolo P, et al: Pharmacological management of IPF. Respirology 2016; 21: 615–625.
36.
Moodley Y, Goh N, Glaspole I, Macansh S, Walters EH, Chapman S, et al: Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project. Respirology 2014; 19: 1088–1091.
37.
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al: Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. Respir Res 2017; 18: 139.
38.
Pittrow D, Klotsche J, Kreuter M, Hoeper MM, Wirtz H, Koschel D, et al: Symptom burden and health related quality of life in patients with idiopathic pulmonary fibrosis in clini cal practice: INSIGHTS-IPF Registry. Value Health 2014; 17:A600.
39.
Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, et al: Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology 2017; 22: 950–956.
40.
Ferrara G, Carlson L, Palm A, Einarsson J, Olivesten C, Skold M: Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. Eur Clin Respir J 2016; 3: 31090.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.